Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486 | 0.91 | CYP1A2 (0.59) | HTTLMNAKMT2ATDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL28940951 | 0.88 | CYP1A2 (0.56) | HTTLMNAKMT2ATDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL321914 | 0.88 | CYP1A2 (0.56) | HTTLMNAKMT2ATDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL23491424 | 0.86 | CYP1A2 (0.54) | HTTLMNAKMT2ATDP1CYP1A2 | |
| SCHEMBL9596694 | 0.83 | — | — | |
| SCHEMBL14275099 | 0.80 | ALDH1A1 (0.62) | HTTLMNAKMT2APOLBCHKA | |
| SCHEMBL14275095 | 0.79 | CYP1A2 (0.52) | TDP1CYP1A2ALDH1A1 | |
| SCHEMBL2616307 | 0.79 | TDP1 (0.81) | HTTLMNAKMT2ATDP1CYP1A2 | |
| SCHEMBL2852512 | 0.79 | HTT (0.57) | HTTLMNAKMT2ATDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL28031922 | 0.78 | CYP1A2 (0.46) | HTTLMNAKMT2ATDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
| EP-3801553-A2 | PRODRUGS OF FULVESTRANT | Kashiv Biosciences, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-105131011-B | Carbamate bridged ring Xanthone derivative, its preparation method and medical usage | 中国药科大学 | 2017-08-25 | — | — | CN | disclosed |
| CN-105131011-A | Carbamate endocyclic xanthone derivative and preparation method and medicinal application thereof | UNIV CHINA PHARMA | 2015-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | HTT 4759/4885LMNA 3107/4885KMT2A 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.